Navigation Links
Velcade (Bortezomib) for Injection Based Therapies Produced,Complete Remission Rates as High as 54 Percent in Patients With,Previously Treated Multiple Myeloma

tion about VELCADE clinical trials, patients and physicians can contact the Millennium Medical Product Information Department at 1-866-VELCADE (1-866-835-2233).

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. Millennium's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. Millennium's website is www.millennium.com.

This press release contains "forward-looking statements," including statements about the Company's growth and development of products. Various important risks may cause the Company's actual results to differ materially from the results indicated by these forward-looking statements, including: adverse results in its drug discovery and clinical development programs; failure to obtain patent protection for its discoveries; commercial limitations imposed by patents owned or controlled by third parties; the Company's dependence upon strategic alliance partners to develop and commercialize products and services based on its work; difficulties or delays in obtaining regulatory approvals to market products and services resulting from its development efforts; product withdrawals; competitive factors; difficulties or delays in manufacturing the Company's products; government and third-party reimbursement rates; the commercial success of VELCADE and INTEGRILIN(R) (eptifibatide) Injection; achieving revenue consistent with internal forecasts; and the requirement for substantial funding to conduct research and development and to expand commercial
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
3. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
4. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Genta Announces Results of Phase 1 Study Using Genasense Administered by Intermittent Subcutaneous Injection
10. Aquavan (Fospropofol Disodium) Injection Data Presented at Digestive Disease Week 2007
11. Hana Biosciences Announces Data to be Presented On Talvesta (Talotrexin) for Injection at The American Association for Cancer Research Annual Meeting
Post Your Comments:
(Date:5/26/2015)... 2015 /CNW/ - Export Development Canada (EDC) today announced a ... Montreal,s Valeant Pharmaceuticals International, Inc. (Valeant), ... The loan is part of a ... is using to fund the repayment of certain outstanding ... pharmaceutical company based in the US. Salix was acquired ...
(Date:5/26/2015)... 26, 2015  Haemonetics Corporation (NYSE: HAE ) ... Investor Relations, will present at The East Coast IDEAS ... June 4 th , 2015 at 2:30pm Eastern time.  ... presentation live via webcast at: http://www.wsw.com/webcast/threepa16/hae ... ) is a global healthcare company dedicated to providing ...
(Date:5/26/2015)... May 26, 2015  Amgen (NASDAQ: AMGN ) ... Phase 3 OPTiM study in the Journal of ... data published in JCO , which were previously ... of Clinical Oncology (ASCO) in 2013 and 2014, demonstrated ... with unresected stage IIIB, IIIC or IV metastatic melanoma ...
Breaking Medicine Technology:EDC provides Valeant Pharmaceuticals with USD 67.5 M to support recent Salix Pharmaceuticals acquisition 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
... Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA ), ... products for central nervous system disorders, today announced it will ... May 5, 2011, before the market opens. A full text ... Mihael H. Polymeropoulos, M.D., President and Chief Executive ...
... NEW BRAUNFELS, Texas, April 22, 2011 One hundred and ... challenge bike riders in the BP MS 150 overcame on ... Sclerosis. Team Freedom, a corporate team sponsored by The ... solutions and services, completed the two-day ride and raised nearly ...
Cached Medicine Technology:Vanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011 2The SCOOTER Store Supports Fight Against Multiple Sclerosis 2
(Date:5/27/2015)... One of America's most cherished actors, James Earl ... that takes a look at the topic of atrial ... abnormal heart rhythm. Those who suffer from atrial fibrillation ... too quickly. , This new segment will take a ... to inform viewers about possible signs that commonly indicate ...
(Date:5/27/2015)... 27, 2015 The Academy of Oncology ... Coast Regional Meeting in Seattle. This intimate gathering, held ... 200 navigation and oncology professionals from west of the ... , “One of the most important things that an ... their needs and do the best it can to ...
(Date:5/26/2015)... 27, 2015 Carey Danis & ... testosterone gel lawsuit . The suit pertains to AndroGel, ... was filed in late April 2015, and a court ... Illinois federal court in mid-May.¹ , Testosterone gel lawsuits ... the Northern District of Illinois. The multidistrict litigation (MDL) ...
(Date:5/26/2015)... Readers who struggle with memory , ... Chester Litvin ’s new book, “ Introduction to ... Trafford Publishing). , Litvin, who is a clinical psychologist, ... This book will guide readers through a series of ... cells . He shares his patented process for reviving ...
(Date:5/26/2015)... Liverpool, Ohio (PRWEB) May 26, 2015 Mr. ... role since 2010, will start working together this week to ... an accomplished career in healthcare executive leadership and strategy. ... CEO prior to the hiring of Mr. Cochran. The Board ... skills will complement the improvement strategies implemented over the past ...
Breaking Medicine News(10 mins):Health News:AONN+’s West Coast Regional Meeting Brings Oncology Nurse and Patient Navigators Together for Two Days of Education and Networking 2Health News:AONN+’s West Coast Regional Meeting Brings Oncology Nurse and Patient Navigators Together for Two Days of Education and Networking 3Health News:Carey Danis & Lowe Comments on Recently Filed Testosterone Gel Lawsuit 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 2Health News:Chester Litvin’s New Book Offers ‘Tune-Up’ for Brain Cells 3
... Harvard Medical School, of more than 100,000 women, indicates ... either psychiatric// illnesses or other conditions, may have an ... about 52,000 women who were taking dopamine antagonists and ... compared for breast cancer rates. It was found that ...
... of Nature Medicine by researchers in Rene Descartes University has ... vaccine which may one day let people quit their AIDS ... promising results, and if confirmed and adapted in humans may ... researchers reported that the new vaccine uses a type of ...
... age people are now increasingly taking to gardening as a ... of beautiful gardens. Though gardening has been proven to have ... gardeners who start with little or no idea of how ... up having severe back pain. ,A recent study of ...
... published in the British Medical Journal suggests that there is ... of their offspring. In contrast to overweight children given birth ... are likely to weigh less than other children. ... 186 grams less than other children and this significant difference ...
... ancient Chinese medical practices that has gained widespread ... suggest that along with other therapies, the traditional ... paediatric patients. ,A recent study which shows ... to acupuncturists, proves the popularity of the traditional ...
... Dietary Supplements & Diabetes ,A recent ... conducted by Dr.Vijay Jayagopal and his colleagues from the ... understand the benefits of dietary supplements on type 2 ... menopausal women with type 2 diabetes who //either received ...
Cached Medicine News:Health News:A Compilation of recent Diabetes Research articles 2
... the best of both worlds, the ... is the latest addition to the ... bipolar cautery instruments for ophthalmic surgery. ... extrusion aspiration and backflush functionality in ...
...
...
...
Medicine Products: